BiotechTube

Sham Injector + FAI Insert

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uveitis

Conditions

Uveitis, Uveitis, Posterior, Uveitis, Intermediate

Trial Timeline

Oct 13, 2021 → Apr 12, 2023

NCT ID
NCT05070728

About Sham Injector + FAI Insert

Sham Injector + FAI Insert is a phase 3 stage product being developed by EyePoint Pharmaceuticals for Uveitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05070728. Target conditions include Uveitis, Uveitis, Posterior, Uveitis, Intermediate.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis were approved

Approved (3) Terminated (8) Active (9)
✅Ixekizumab Prefilled SyringeEli LillyApproved
✅AdalimumabAbbVieApproved
✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved
🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
🔄Baricitinib + AdalimumabEli LillyPhase 3
🔄adalimumabAbbViePhase 3
🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05070728Phase 3Terminated

Competing Products

20 competing products in Uveitis

See all competitors
ProductCompanyStageHype Score
triamcinolone acetonide (Triesence®)Clearside BiomedicalPhase 1/2
22
4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
30
Baricitinib + AdalimumabEli LillyPhase 3
44
Ixekizumab Prefilled SyringeEli LillyApproved
39
adalimumabAbbViePhase 3
40
Adalimumab + Prednisone + PlaceboAbbViePhase 3
40
Adalimumab + Prednisone + PlaceboAbbViePhase 3
40
AdalimumabAbbVieApproved
43
FTY720 + Oral CorticosteroidNovartisPhase 2
27
AIN457NovartisPhase 3
32
MyforticNovartisPre-clinical
22
AIN457 + AIN457 + Placebo AIN457NovartisPhase 3
32
LFG316 + Conventional TherapyNovartisPhase 2
35
RanibizumabNovartisPhase 2
35
AIN457 + PlaceboNovartisPhase 3
32
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
AEB071NovartisPhase 2
35
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
Myfortic + DecortinNovartisPhase 3
40
AIN457 + AIN 457 + AIN457NovartisPhase 2
35